Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1016/j.jmig.2021.10.007 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Renal anemia and hyporesponsiveness to ESA for preservation of residual kidney function in patients undergoing peritoneal dialysis.
Sci Rep
January 2025
Division of Kidney and Dialysis, Department of Internal Medicine, Hyogo College of Medicine, Nishinomiya, Japan.
Preservation of residual kidney function (RKF) is important in patients undergoing peritoneal dialysis (PD). We aimed to examine the association between anemia management and residual urine output using data from a nationwide survey of dialysis patients. After excluding patients with anuria at baseline from the Total cohort of 2,712, 659 of 1,640 patients developed anuria during a median follow-up of 2.
View Article and Find Full Text PDFComparing residual kidney function equations based on β2-microglobulin in Chinese patients undergoing continuous ambulatory peritoneal dialysis.
Perit Dial Int
January 2025
Department of Nephrology, Hangzhou TCM Hospital Affiliated to Zhejiang Chinese Medical University, China.
Background: Few studies have evaluated the predictive capability of equations for residual kidney function (RKF) in patients undergoing peritoneal dialysis (PD). Moreover, the applicability of each equation remains unclear. Therefore, we aimed to evaluate the performances of the estimated RKF (eRKF) equations of Shafi, Steubl, and Jaques in Chinese patients undergoing continuous ambulatory peritoneal dialysis (CAPD).
View Article and Find Full Text PDFResistant and Apparently Resistant Hypertension in Peritoneally Dialyzed Patients.
J Clin Med
January 2025
Department of Nephrology, Dialysis and Internal Diseases, Medical University of Warsaw, 02-097 Warsaw, Poland.
Hypertension in chronic kidney disease patients is very common. The definition of resistant hypertension in the general population is as follows: uncontrolled blood pressure (BP) on three or more hypotensive agents in adequate doses, or when patients are on four or more hypotensive agent categories irrespective of the BP control, with diuretics included in the therapy. However, these resistant hypertension definitions do not apply to the setting of end-stage kidney disease.
View Article and Find Full Text PDFEstablishment of permanent peritoneal PleurX catheter as palliative treatment of malignant ascites.
Dan Med J
November 2024
Department of Gastrointestinal Surgery, Aarhus University Hospital.
Introduction: Refractory malignant ascites (RMA) is a manifestation of end-stage cancer disease with a major impact on quality of life due to the symptom burden and need for repeated hospitalisations. We previously described the implantation of the permanent PleurX catheter as a treatment of RMA. The present study aimed to evaluate and describe our experience with the permanent PleurX catheter system in the largest cohort to date.
View Article and Find Full Text PDFProbiotic interventions in peritoneal dialysis: A review of underlying mechanisms and therapeutic potentials.
World J Nephrol
December 2024
Department of Nephrology and Dialysis, State Institution "O.O. Shalimov National Scientific Center of Surgery and Transplantology of the National Academy of Medical Science of Ukraine", Kyiv 03680, Ukraine.
Peritoneal dialysis (PD) is a commonly used modality for kidney replacement therapy for patients with end-stage kidney disease (ESKD). PD offers many benefits, including home-based care, greater flexibility, and preservation of residual kidney function compared to in-center hemodialysis. Nonetheless, patients undergoing PD often face significant challenges, including systemic inflammation, PD-related peritonitis, metabolic disorders, and cardiovascular issues that can negatively affect their quality of life and treatment outcomes.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!